The insulin-like growth factor 1 receptor in cancer: Old focus, new future

被引：144

作者：

Hartog, Hermien

Wesseling, Jelle

Boezen, H. Marike

van der Graaf, Winette T. A.

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

[2] Univ Groningen, Med Ctr, Dept Oncol, Groningen, Netherlands

[3] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands

[4] Univ Groningen, Med Ctr, Dept Epidemiol, Groningen, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2007年 / 43卷 / 13期

关键词：

insulin-like growth factor 1 receptor; insulin receptor; hybrid receptor; tyrosine kinase inhibitors; targeted therapy; growth factor receptor; antibody; cancer;

D O I：

10.1016/j.ejca.2007.05.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The importance of insulin-like growth factor I receptor (IGF-1R) signalling in malignant behaviour of tumour cells is well established. Currently, development of drugs targeting the IGF-1R as anticancer treatment is emerging. Several IGF-1R targeting strategies are being investigated in phases 1 and 11 clinical trials. interactions of IGF-1R with insulin receptor, however, might complicate efficiency and tolerability of such drugs. This review describes mechanisms, recent developments and potential limitations of IGF-1R antibodies and tyrosine kinase inhibitors. (C) 2007 Elsevier Ltd. All rights reserved.

引用

收藏

页码：1895 / 1904

页数：10

相关论文

共 106 条

[51] Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade [J].

Liao, YD ;

Vbel, U ;

Grobholz, R ;

Hermani, A ;

Biol, D ;

Trojan, L ;

Angel, P ;

Mayer, D .

HUMAN PATHOLOGY, 2005, 36 (11) :1186-1196

[52]

LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K

[53] Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis [J].

Lopez, T ;

Hanahan, D .

CANCER CELL, 2002, 1 (04) :339-353

[54] A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity [J].

Lu, D ;

Zhang, HF ;

Koo, H ;

Tonra, J ;

Balderes, P ;

Prewett, M ;

Corcoran, E ;

Mangalampalli, V ;

Bassi, R ;

Anselma, D ;

Patel, D ;

Kang, XQ ;

Ludwig, DL ;

Hicklin, DJ ;

Bohlen, P ;

Witte, L ;

Zhu, ZP .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (20) :19665-19672

[55]

Maloney EK, 2003, CANCER RES, V63, P5073

[56] Preclinical in vivo study of new insulin-like growth factor-1 receptor -: Specific inhibitor in Ewing's sarcoma [J].

Manara, Maria C. ;

Landuzzi, Lorena ;

Nanni, Patrizia ;

Nicoletti, Giordano ;

Zambelli, Diana ;

Lollini, Pier Luigi ;

Nanni, Cristina ;

Hofmann, Francesco ;

Garcia-Echeverria, Carlos ;

Picci, Piero ;

Scotlandi, Katia .

CLINICAL CANCER RESEARCH, 2007, 13 (04) :1322-1330

[57]

Mathieu MC, 1997, P ASSOC AM PHYSICIAN, V109, P565

[58] Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model [J].

Menu, E ;

Jernberg-Wiklund, H ;

Stromberg, T ;

De Raeve, H ;

Girnita, L ;

Larsson, O ;

Axelson, M ;

Asosingh, K ;

Nilsson, K ;

Van Camp, B ;

Vanderkerken, K .

BLOOD, 2006, 107 (02) :655-660

[59] What clinicians need to know about antioestrogen resistance in breast cancer therapy [J].

Milano, Amalia ;

Dal Lago, Lissandra ;

Sotiriou, Christos ;

Piccart, Martine ;

Cardoso, Fatima .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (16) :2692-2705

[60] Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors [J].

Mitsiades, CS ;

Mitsiades, NS ;

McMullan, CJ ;

Poulaki, V ;

Shringarpure, R ;

Akiyama, M ;

Hideshima, T ;

Chauhan, D ;

Joseph, M ;

Libermann, TA ;

García-Echeverría, C ;

Pearson, MA ;

Hofmann, F ;

Anderson, KC ;

Kung, AL .

CANCER CELL, 2004, 5 (03) :221-230

← 1 2 3 4 5 6 7 8 9 10 →